The following represents disclosure information provided by authors of this abstract. The ASCO Scientific Program Committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered self-held and compensated unless otherwise noted. Employment/Leadership relationships are considered compensated employment unless otherwise noted. L = Leadership, U = Uncompensated, I = Immediate Family Member, B = Both Myself and Immediate Family Member, Inst = My Institution
Impact of erlotinib activity on overall survival in non small cell lung cancer patients: Is the post progression survival a new paradigm?
Tindara Franchina
No relevant relationships to disclose
Alessandro Russo
No relevant relationships to disclose
Claudia Proto
No relevant relationships to disclose
Giuseppe Chiofalo
No relevant relationships to disclose
Maria Picciotto
No relevant relationships to disclose
Antonino Scimone
No relevant relationships to disclose
Giuseppe Toscano
No relevant relationships to disclose
Rosa Berenato
No relevant relationships to disclose
Laura Noto
No relevant relationships to disclose
Vincenzo Adamo
No relevant relationships to disclose